On September 1, 2016, the S.E.C. Qualified BioSculpture Technology’s Tier 2 Regulation A Offering to fund development and clinical testing of our patented endoscopic treatment of obesity, metabolic syndrome, and type 2 diabetes mellitus. Issuer: BioSculpture Technology, Inc.; CUSIP Number: 09074G 106; ISIN NUMBER: US09074G1067; Issue Description: COM. This Offering terminated on August 31, 2017.
Our Regulation A Offering which qualified on September 1, 2016 terminated on August 31, 2017 and links are provided to those Offering documents for informational purposes only.
Innovative Solutions Based on ScienceTM
BioSculpture Technology, Inc. is a commercial-stage medical device manufacturer of liposuction surgical instruments for surgeons. It offers the FDA-cleared Twin Cannula Assisted Liposuction (“TCAL”) Airbrush® Liposculptor II, Intellimotion® controllers, Airbrush® cannula sets, and multicore connectors. The company also provides warranty repairs, physician referrals, as well as offers license options. It serves customers through a network of manufacturer representatives. The company was founded in 2001, incorporated in Delaware, and is based in West Palm Beach, Florida.
Our Corporate Mission is to unleash the artist in the surgeon® for cosmetic procedures, develop innovative solutions based on science™ for treatment applications, and be a world leading manufacturer and developer of medical devices and procedures for handling adipose tissue targeting: the liposuction and body sculpting market, the bariatric treatment market, and the fat autograft and adipocyte-derived stem cell processing markets.
The Company is developing a patented minimally invasive method and device for the endoscopic removal of visceral or “belly” fat, Endoscopic Visceral Lipectomy or “EVL” as a new treatment of obesity, metabolic syndrome and type 2 diabetes mellitus. Three U.S. patents have been allowed on both the method and device and numerous others are pending. BST filed its Form 1-A with the S.E.C. to fund EVL development and commercialization and initiate becoming a public company. Bringing this highly disruptive EVL technology to market is BST’s highest priority. Although safety and efficacy studies are yet to be performed and regulatory approvals obtained, the Company believes EVL has the potential of doing for obesity treatment what LASIK did for vision correction.
The Company will convert production to a next generation version of its pneumatic TCAL system, the Airbush® Liposculptor IIE, a sleeker electrical wand. The Company also is developing a single cannula Power Assisted Liposuction (“PAL”) device, the Airbrush® Liposculptor III, the next generation of a tissue aspiration technology our Founder also invented but successfully licensed to UAM, NuMed, Byron Medical, and Mentor.